CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Carbamazepine

卡马西平 杂质对照品Carbamazepine Impurities

EP33 个杂质条目33 impurity entries

本页汇总 卡马西平 的 33 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 33 impurity reference standards of Carbamazepine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 卡马西平(Carbamazepine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesSonochemical degradation of the persistent pharmaceutical carbamazepine
    Journal of environmental management · 2013 · Tran N et al.  ·  PMID 24140484  ·  DOI
  2. 杂质研究Impurity studiesQuantitative bioanalytical and analytical method development of dibenzazepine derivative, carbamazepine: A review
    Journal of pharmaceutical analysis · 2015 · Datar PA  ·  PMID 29403934  ·  DOI
  3. 杂质研究Impurity studiesCilostazol geno-protective effects mitigate carbamazepine-induced genotoxicity in human cultured blood lymphocytes
    Toxicology reports · 2024 · Al Momany EM et al.  ·  PMID 39654995  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma
    Analytical and bioanalytical chemistry · 2010 · Fortuna A et al.  ·  PMID 20401721  ·  DOI
  5. 分析方法Analytical Methods[Development of a carbamazepine determination method based on high-performance liquid chromatography with diode array]
    Sudebno-meditsinskaia ekspertiza · 2024 · Khabieva NA et al.  ·  PMID 38353011  ·  DOI

卡马西平 —— 原料药与杂质对照品Carbamazepine — drug substance & impurities

共 33 个条目(含原料药本体)33 items incl. the drug substance
Carbamazepine Impurity 1(Carbamazepine EP Impurity A) structure
EPA
卡马西平杂质1(卡马西平EP杂质A)Carbamazepine Impurity 1(Carbamazepine EP Impurity A)
Carbamazepine Impurity 1(Carbamazepine EP Impurity A)
CAS No.3564-73-6
Chemical FormulaC15H14N2O
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 3(Carbamazepine EP Impurity C) structure
EPC
卡马西平杂质3(卡马西平EP杂质C)Carbamazepine Impurity 3(Carbamazepine EP Impurity C)
Carbamazepine Impurity 3(Carbamazepine EP Impurity C)
CAS No.1219170-51-0
Chemical FormulaC16H13N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 29 (N-Nitroso Carbamazepine EP Impurity D) structure
EPD
卡马西平杂质29 (N-亚硝基卡马西平EP杂质D)Carbamazepine Impurity 29 (N-Nitroso Carbamazepine EP Impurity D)
Carbamazepine Impurity 29 (N-Nitroso Carbamazepine EP Impurity D)
CAS No.38652-29-8
Chemical FormulaC14H10N2O
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 22 (N-Nitroso Carbamazepine EP Impurity E) structure
EPE
卡马西平杂质22 (N-亚硝基卡马西平EP杂质E)Carbamazepine Impurity 22 (N-Nitroso Carbamazepine EP Impurity E)
Carbamazepine Impurity 22 (N-Nitroso Carbamazepine EP Impurity E)
CAS No.7458-08-4
Chemical FormulaC14H12N2O
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 6(Carbamazepine EP Impurity F) structure
EPF
卡马西平杂质6(卡马西平EP杂质F)Carbamazepine Impurity 6(Carbamazepine EP Impurity F)
Carbamazepine Impurity 6(Carbamazepine EP Impurity F)
CAS No.33948-22-0
Chemical FormulaC15H10ClNO
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 7(Carbamazepine EP Impurity G) structure
EPG
卡马西平杂质7(卡马西平EP杂质G)Carbamazepine Impurity 7(Carbamazepine EP Impurity G)
Carbamazepine Impurity 7(Carbamazepine EP Impurity G)
CAS No.59690-97-0
Chemical FormulaC15H11BrN2O
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 4-d2(Carbamazepine EP Impurity D-d2) structure
EPD-D2
卡马西平杂质4-d2(卡马西平EP杂质D-d2)Carbamazepine Impurity 4-d2(Carbamazepine EP Impurity D-d2)
Carbamazepine Impurity 4-d2(Carbamazepine EP Impurity D-d2)
CAS No.91704-65-3
Chemical FormulaC14H9D2N
Purity>95%询价On request
Carbamazepine Impurity 8 structure
8
卡马西平杂质8Carbamazepine Impurity 8
Carbamazepine Impurity 8
CAS No.40421-05-4
Chemical FormulaC15H10BrNO
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 9 structure
9
卡马西平杂质9Carbamazepine Impurity 9
Carbamazepine Impurity 9
CAS No.70401-31-9
Chemical FormulaC15H13N
Purity>95%现货In stock
10mg25mg50mg100mg
Carbamazepine Impurity 10 (2-Methyl Carbamazepine) structure
10
卡马西平杂质10Carbamazepine Impurity 10 (2-Methyl Carbamazepine)
Carbamazepine Impurity 10 (2-Methyl Carbamazepine)
CAS No.70401-32-0
Chemical FormulaC16H14N2O
Purity>95%现货In stock
10mg25mg50mg100mg
Carbamazepine Impurity 11 structure
11
卡马西平杂质11Carbamazepine Impurity 11
Carbamazepine Impurity 11
CAS No.106758-94-5
Chemical FormulaC15H14N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 12 structure
12
卡马西平杂质12Carbamazepine Impurity 12
Carbamazepine Impurity 12
CAS No.36507-30-9
Chemical FormulaC15H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 14 structure
14
卡马西平杂质14Carbamazepine Impurity 14
Carbamazepine Impurity 14
CAS No.1020719-39-4
Chemical FormulaC15H14N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 15 structure
15
卡马西平杂质15Carbamazepine Impurity 15
Carbamazepine Impurity 15
CAS No.68011-67-6
Chemical FormulaC15H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 16 structure
16
卡马西平杂质16Carbamazepine Impurity 16
Carbamazepine Impurity 16
CAS No.59690-92-5
Chemical FormulaC15H11ClN2O
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 17 structure
17
卡马西平杂质17Carbamazepine Impurity 17
Carbamazepine Impurity 17
CAS No.68011-66-5
Chemical FormulaC15H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 18 structure
18
卡马西平杂质18Carbamazepine Impurity 18
Carbamazepine Impurity 18
CAS No.16968-19-7
Chemical FormulaC14H12N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 19 structure
19
卡马西平杂质19Carbamazepine Impurity 19
Carbamazepine Impurity 19
CAS No.1261034-93-8
Chemical FormulaC14H11Br2N
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 20 structure
20
卡马西平杂质20Carbamazepine Impurity 20
Carbamazepine Impurity 20
CAS No.40421-03-2
Chemical FormulaC15H10Br2ClNO
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 21 structure
21
卡马西平杂质21Carbamazepine Impurity 21
Carbamazepine Impurity 21
CAS No.143667-53-2
Chemical FormulaC15H9BrClNO
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 23 structure
23
卡马西平杂质23Carbamazepine Impurity 23
Carbamazepine Impurity 23
CAS No.791633-38-0
Chemical FormulaC15H13ClN2O
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 24 structure
24
卡马西平杂质24Carbamazepine Impurity 24
Carbamazepine Impurity 24
CAS No.52249-32-8
Chemical FormulaC15H13N
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 26 structure
26
卡马西平杂质26Carbamazepine Impurity 26
Carbamazepine Impurity 26
CAS No.53003-61-5
Chemical FormulaC15H9Br2NO
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 27 structure
27
卡马西平杂质27Carbamazepine Impurity 27
Carbamazepine Impurity 27
CAS No.2512216-68-9
Chemical FormulaC15H11Br2NO
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 28 structure
28
卡马西平杂质28Carbamazepine Impurity 28
Carbamazepine Impurity 28
CAS No.19209-60-0
Chemical FormulaC16H13NO
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 31 structure
31
卡马西平杂质31Carbamazepine Impurity 31
Carbamazepine Impurity 31
CAS No.1217528-81-8
Chemical FormulaC15H14N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 34 structure
34
卡马西平杂质34Carbamazepine Impurity 34
Carbamazepine Impurity 34
CAS No.79752-06-0
Chemical FormulaC14H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 40 structure
40
卡马西平杂质40Carbamazepine Impurity 40
Carbamazepine Impurity 40
CAS No.866874-00-2
Chemical FormulaC16H12BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 46 structure
46
卡马西平杂质46Carbamazepine Impurity 46
Carbamazepine Impurity 46
CAS No.3335-98-6
Chemical FormulaC14H11NO
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 47 structure
47
卡马西平杂质47Carbamazepine Impurity 47
Carbamazepine Impurity 47
CAS No.353497-35-5
Chemical FormulaC16H15NO4
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 48 structure
48
卡马西平杂质48Carbamazepine Impurity 48
Carbamazepine Impurity 48
CAS No.41359-12-0
Chemical FormulaC15H11BrClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Carbamazepine Impurity 14-d4 structure
14-D4
卡马西平杂质14-d4Carbamazepine Impurity 14-d4
Carbamazepine Impurity 14-d4
CAS No.1188265-49-7
Chemical FormulaC15H10D4N2O2
Purity>95%询价On request
Carbamazepine Impurity 46-d5 structure
46-D5
卡马西平杂质46-d5Carbamazepine Impurity 46-d5
Carbamazepine Impurity 46-d5
CAS No.1189871-32-6
Chemical FormulaC14H6D5NO
Purity>95%询价On request
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

卡马西平 —— 研究文献与合成路线Carbamazepine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 卡马西平 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Carbamazepine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Mechanistic role of chloride in enhancing carbamazepine degradation by dithionite-activated sodium hypochlorite
    Song W, Fang H, Zhang Z, et al. · Journal of hazardous materials · 2026 · 被引 1cited 1
  2. Influence of solid form impurity on punch sticking propensity of carbamazepine
    Elsergany RN, Joshi VC, Sun CC · International journal of pharmaceutics · 2026
  3. Tuning reactive species formation in dithionite-based advanced reduction processes for the degradation of carbamazepine and perfluorooctanoic acid
    Tian K, Cabooter D, Xiong M, et al. · Water research · 2026
  4. Advanced Chlorine Photolysis for Carbamazepine Degradation: Tuning Radicals for Dissolved Organics
    Osei-Appau C, Kamat M, Petit E, et al. · ACS ES&T water · 2026
  5. Stability indicating spectrophotometric methods for quantitative determination of carbamazepine and its degradation product, iminostilbene, in pure form and pharmaceutical formulations
    Naguib IA, Elyazeed NA, Elroby FA, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2019 · 被引 4cited 4
  6. Appraisal of the greenness profile of a chromatographic method for the simultaneous estimation of carbamazepine and oxcarbazepine, along with two potential impurities and three formulation excipients
    Abdelwahab NS, Abdelrahman MM · RSC advances · 2021 · 被引 3cited 3

合成与制备工艺专利Synthesis & process patents

  1. PARENTERAL PREPARATION CONTAINING CARBAMAZEPINE OR ITS DERIVATIVE
    HOOGEVEST PETER VAN · 公开号 JP2005281314JP2005281314 · 2005
  2. Carbamazepine medicine and its preparing method
    PU YIHUA, SUN GUOJIAN, YU FENG · 公开号 CN1616433CN1616433 · 2005

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

卡马西平 杂质谱研究要点Carbamazepine — impurity profiling notes

下面这些是拿到 卡马西平 的 33 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 33 impurity entries for Carbamazepine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances